Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology Group

Basit Öğe Kaydı
dc.contributor.authorTunbekici, Salih
dc.contributor.authorSahin, Gokhan
dc.contributor.authorOn, Sercan
dc.contributor.authorOruc, Ahmet
dc.contributor.authorEryilmaz, Melek Karakurt
dc.contributor.authorSakin, Abdullah
dc.contributor.authorCoskun, Alper
dc.date.accessioned2026-04-04T13:37:40Z
dc.date.available2026-04-04T13:37:40Z
dc.date.issued2026
dc.departmentİnönü Üniversitesi
dc.description.abstractSacituzumab govitecan (SG) is an antibody-drug conjugate approved for metastatic or unresectable locally advanced triple-negative breast cancer (mTNBC) after at least two prior systemic therapies, yet real-world evidence remains limited. We conducted a retrospective, multicenter study including 285 patients with unresectable locally advanced or metastatic TNBC treated with SG across 52 oncology centers in Turkey. Median progression-free and overall survival were 5.4 months (95% confidence interval [CI], 4.6-6.2) and 12.2 months (95% CI, 10.5-13.9), respectively, with a 12-month overall survival rate of 49.2%. The objective response rate and disease control rate in evaluable patients were 36.8% and 63.9%. Grades 3-4 adverse events, mainly neutropenia, occurred in 44.2% of patients. Dose reductions were needed in 20% of cases; no treatment-related deaths were reported. Our large real-world cohort reinforces the effectiveness and manageable safety profile of SG, mirroring pivotal trials, and highlights its value as a therapeutic option in diverse and heavily pretreated mTNBC populations.
dc.identifier.doi10.1002/ijc.70213
dc.identifier.endpage1890
dc.identifier.issn0020-7136
dc.identifier.issn1097-0215
dc.identifier.issue7
dc.identifier.orcid0000-0003-3060-377X
dc.identifier.orcid0000-0003-0333-5191
dc.identifier.orcid0000-0002-9153-6921
dc.identifier.orcid0009-0009-6747-8264
dc.identifier.orcid0000-0003-1478-9383
dc.identifier.orcid0000-0001-6654-3815
dc.identifier.orcid0000-0001-9035-4846
dc.identifier.pmid41147655
dc.identifier.scopus2-s2.0-105020597792
dc.identifier.scopusqualityQ1
dc.identifier.startpage1881
dc.identifier.urihttps://doi.org/10.1002/ijc.70213
dc.identifier.urihttps://hdl.handle.net/11616/109979
dc.identifier.volume158
dc.identifier.wosWOS:001601304600001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofInternational Journal of Cancer
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250329
dc.subjectreal-world study
dc.subjectsacituzumab govitecan
dc.subjecttriple-negative breast cancer
dc.titleReal-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology Group
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu